论文部分内容阅读
目的:探讨树突状细胞(DCs)和细胞因子诱导的杀伤(CIK)细胞免疫治疗联合化疗对晚期非小细胞肺癌患者的治疗效果。方法:将我院2012年2月到2014年2月就诊的72例晚期非小细胞肺癌患者随机分为对照组(n=36,单纯化疗组)和实验组(n=36,DCs-CIK细胞免疫联合化疗组)。比较两组患者治疗后的疗效、治疗前后免疫功能,并运用Kamofsky(KPS)评分来评估两组患者治疗后生活质量的改善情况。结果:实验组的疾病控制率(DCR)77.78%显著高于对照组的52.78%(P<0.05)。治疗后实验组患者外周血CD3+、CD8+及NK细胞所占的比值较治疗前均上升显著(P<0.05);治疗后对照组患者外周血CD3+、CD8+及NK细胞所占的比值较治疗前下降显著(P<0.05)。治疗后实验组KPS评分提高率明显高于对照组(P<0.05)。结论:DCs-CIK细胞免疫联合化疗能够提高晚期非小细胞肺癌患者的DCR,且显著改善患者的免疫功能和生活质量。
Objective: To investigate the therapeutic effect of dendritic cells (DCs) and cytokine-induced cytotoxicity (CIK) cell immunotherapy combined with chemotherapy on patients with advanced non-small cell lung cancer. Methods: Seventy-two patients with advanced NSCLC who were treated in our hospital from February 2012 to February 2014 were randomly divided into control group (n = 36, chemotherapy group) and experimental group (n = 36, DCs-CIK cells Immunotherapy combined with chemotherapy group). The curative effect after treatment, the immune function before and after treatment, and the improvement of quality of life after treatment were evaluated by Kamofsky (KPS) score. Results: The experimental group’s disease control rate (DCR) 77.78% was significantly higher than that of the control group 52.78% (P <0.05). After treatment, the ratio of CD3 +, CD8 + and NK cells in experimental group increased significantly compared with that before treatment (P <0.05). After treatment, the ratio of CD3 +, CD8 + and NK cells in peripheral blood of the experimental group decreased compared with that before treatment Significant (P <0.05). After treatment, the improvement rate of KPS score in experimental group was significantly higher than that in control group (P <0.05). Conclusions: DCs-CIK combined with cell-mediated immunotherapy can improve the DCR in patients with advanced non-small cell lung cancer and significantly improve the immune function and quality of life.